Verrica Pharmaceuticals Inc. Forecasted to Post Q2 2022 Earnings of ($0.36) Per Share (NASDAQ:VRCA)

Verrica Pharmaceuticals Inc. (NASDAQ:VRCAGet Rating) – Analysts at Jefferies Financial Group issued their Q2 2022 EPS estimates for Verrica Pharmaceuticals in a research report issued on Monday, May 9th. Jefferies Financial Group analyst C. Ezell forecasts that the company will earn ($0.36) per share for the quarter. Jefferies Financial Group also issued estimates for Verrica Pharmaceuticals’ Q3 2022 earnings at ($0.46) EPS, Q4 2022 earnings at ($0.61) EPS, FY2022 earnings at ($1.79) EPS, FY2023 earnings at ($1.05) EPS, FY2024 earnings at $0.14 EPS, FY2025 earnings at $0.97 EPS and FY2026 earnings at $2.43 EPS.

Verrica Pharmaceuticals (NASDAQ:VRCAGet Rating) last released its quarterly earnings data on Wednesday, March 2nd. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.13.

VRCA has been the subject of several other reports. Brookline Capital Management reaffirmed a “buy” rating on shares of Verrica Pharmaceuticals in a research report on Thursday, March 10th. Brookline Capital Acquisition began coverage on shares of Verrica Pharmaceuticals in a research report on Thursday, March 10th. They set a “buy” rating and a $20.00 price objective for the company. Needham & Company LLC decreased their price objective on shares of Verrica Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, March 3rd. Zacks Investment Research raised shares of Verrica Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 16th. Finally, HC Wainwright reissued a “buy” rating on shares of Verrica Pharmaceuticals in a research report on Monday, March 7th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $18.00.

Verrica Pharmaceuticals stock opened at $5.65 on Thursday. The stock has a market cap of $155.48 million, a P/E ratio of -4.38 and a beta of 1.96. The company has a fifty day simple moving average of $7.69 and a 200-day simple moving average of $8.91. Verrica Pharmaceuticals has a 12-month low of $5.50 and a 12-month high of $14.79.

Several large investors have recently made changes to their positions in the company. BlackRock Inc. raised its holdings in shares of Verrica Pharmaceuticals by 23.1% in the fourth quarter. BlackRock Inc. now owns 794,466 shares of the company’s stock valued at $7,278,000 after buying an additional 149,248 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Verrica Pharmaceuticals by 11.8% in the third quarter. Geode Capital Management LLC now owns 238,069 shares of the company’s stock valued at $2,975,000 after buying an additional 25,089 shares during the last quarter. Morgan Stanley raised its holdings in shares of Verrica Pharmaceuticals by 2,540.4% in the second quarter. Morgan Stanley now owns 122,065 shares of the company’s stock valued at $1,380,000 after buying an additional 117,442 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Verrica Pharmaceuticals by 466.6% in the fourth quarter. Millennium Management LLC now owns 94,220 shares of the company’s stock valued at $863,000 after buying an additional 77,590 shares during the last quarter. Finally, MML Investors Services LLC raised its holdings in shares of Verrica Pharmaceuticals by 13.4% in the fourth quarter. MML Investors Services LLC now owns 50,875 shares of the company’s stock valued at $466,000 after buying an additional 6,000 shares during the last quarter. 34.58% of the stock is owned by institutional investors and hedge funds.

Verrica Pharmaceuticals Company Profile (Get Rating)

Verrica Pharmaceuticals Inc, a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts.

Further Reading

Earnings History and Estimates for Verrica Pharmaceuticals (NASDAQ:VRCA)

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.